Stem Cell Therapy for Parkinson’s Disease
Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s. It is primarily characterized by motor symptoms such as tremors, rigidity, and slowed movement, and in later stages, it often progresses to include cognitive decline and dementia.
The root cause of Parkinson’s is the progressive degeneration of dopamine-producing neurons in the brain. As dopamine levels fall, motor control becomes increasingly impaired. While current medications aim to increase dopamine levels and manage symptoms, they do not address the underlying disease process.
The Role of Inflammation in Parkinson’s
Like many neurodegenerative diseases, chronic inflammation in the brain—or neuroinflammation—is now recognized as a major contributor to Parkinson’s progression. This inflammation damages neurons and accelerates dopamine depletion.
How Stem Cell Therapy May Help
Umbilical cord stem cells, particularly mesenchymal stem cells (MSCs), show significant promise in addressing Parkinson’s disease at its root. These cells are:
- Anti-inflammatory – helping reduce neuroinflammation that contributes to neuron damage
- Neuroprotective – releasing growth factors that support and potentially repair existing neurons
- Regenerative – promoting new cellular connections and supporting overall brain health
Since 2010, stem cell therapy has been studied in patients with Parkinson’s disease, and several clinical trials have demonstrated meaningful improvements.
Research Highlights
- Patients receiving stem cell therapy have reported reduced motor and non-motor symptoms, including improvements in mobility, coordination, sleep, and mood.
- Ongoing trials continue to explore how early intervention may slow disease progression and enhance quality of life.